18
|
Villar IC, Panayiotou CM, Sheraz A, Madhani M, Scotland RS, Nobles M, Kemp-Harper B, Ahluwalia A, Hobbs AJ. Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. Cardiovasc Res 2007; 74:515-25. [PMID: 17391657 PMCID: PMC3503309 DOI: 10.1016/j.cardiores.2007.02.032] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2006] [Revised: 02/07/2007] [Accepted: 02/26/2007] [Indexed: 11/25/2022] Open
Abstract
OBJECTIVE C-type natriuretic peptide (CNP) has recently been suggested to represent an endothelium-derived hyperpolarising factor (EDHF) in the mammalian resistance vasculature and, as such, important in the regulation of local blood flow and systemic blood pressure. Additionally, this peptide has been shown to protect against ischaemia-reperfusion injury and inhibits leukocyte and platelet activation. Herein, we use a novel, selective natriuretic peptide receptor-C (NPR-C) antagonist (M372049) to highlight the pivotal contribution of CNP/NPR-C signalling in the EDHF-dependent regulation of vascular tone and investigate the mechanism(s) underlying the release and biological activity of CNP. METHODS In vitro pharmacological investigation was conducted in rat (Sprague-Dawley) aorta and mesenteric resistance arteries. Relaxant responses to CNP, atrial natriuretic peptide (ANP), the nitric oxide donor spermine-NONOate (SPER-NO) and the endothelium-dependent vasodilator, acetylcholine (ACh) were examined in the absence and presence of M372049 or inhibitor cocktails shown previously to block endothelium-dependent dilatation in the resistance vasculature. RT-PCR was employed to characterize the expression of NPR subtypes in the vessels studied. RESULTS M372049 produced concentration-dependent inhibition of the vasorelaxant activity of CNP in rat isolated mesenteric resistance arteries but not aorta; in contrast, M372049 did not affect relaxations to ANP or SPER-NO in either vessel. M372049 or ouabain alone produced small, significant inhibition of EDHF-dependent relaxations in mesenteric arteries and in combination acted synergistically to abolish such responses. A combination of M372049 with established inhibitors of EDHF-dependent relaxation revealed that multiple, distinct pathways coordinate the bioactivity of EDHF in the resistance vasculature, and that CNP/NPR-C signalling represents a major component. CONCLUSIONS These data substantiate CNP/NPR-C signalling as a fundamental pathway underlying EDHF-dependent regulation of vascular tone in the rat mesenteric resistance vasculature. An increased understanding of the physiological roles of CNP/NPR-C signalling in the vasculature (now facilitated by the identification of a selective NPR-C antagonist) should aid determination of the (patho)physiological importance of EDHF and might provide the rationale for the design of novel therapeutics.
Collapse
Affiliation(s)
- Inmaculada C. Villar
- Clinical Pharmacology, William Harvey Research Institute, Bart’s and The London, Charterhouse Square, London EC1M 6BQ, UK
| | - Catherine M. Panayiotou
- Wolfson Institute for Biomedical Research, University College London, Cruciform Building, Gower Street, London WC1E 6AE, UK
| | - Adil Sheraz
- Clinical Pharmacology, William Harvey Research Institute, Bart’s and The London, Charterhouse Square, London EC1M 6BQ, UK
| | - Melanie Madhani
- Wolfson Institute for Biomedical Research, University College London, Cruciform Building, Gower Street, London WC1E 6AE, UK
| | - Ramona S. Scotland
- Clinical Pharmacology, William Harvey Research Institute, Bart’s and The London, Charterhouse Square, London EC1M 6BQ, UK
| | - Muriel Nobles
- Wolfson Institute for Biomedical Research, University College London, Cruciform Building, Gower Street, London WC1E 6AE, UK
| | - Barbara Kemp-Harper
- Department of Pharmacology, Monash University, PO Box 13E, VIC 3800, Australia
| | - Amrita Ahluwalia
- Clinical Pharmacology, William Harvey Research Institute, Bart’s and The London, Charterhouse Square, London EC1M 6BQ, UK
| | - Adrian J. Hobbs
- Wolfson Institute for Biomedical Research, University College London, Cruciform Building, Gower Street, London WC1E 6AE, UK
- Author for correspondence at the above address: Tel.: +44-(0)20-7679-6611, Fax.: +44(0)20-7691-3104,
| |
Collapse
|
20
|
Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H.S. AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Müller-Esterl W, Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006; 116:2552-61. [PMID: 16955146 PMCID: PMC1555649 DOI: 10.1172/jci28371] [Citation(s) in RCA: 357] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2006] [Accepted: 07/11/2006] [Indexed: 01/14/2023] Open
Abstract
ROS are a risk factor of several cardiovascular disorders and interfere with NO/soluble guanylyl cyclase/cyclic GMP (NO/sGC/cGMP) signaling through scavenging of NO and formation of the strong oxidant peroxynitrite. Increased oxidative stress affects the heme-containing NO receptor sGC by both decreasing its expression levels and impairing NO-induced activation, making vasodilator therapy with NO donors less effective. Here we show in vivo that oxidative stress and related vascular disease states, including human diabetes mellitus, led to an sGC that was indistinguishable from the in vitro oxidized/heme-free enzyme. This sGC variant represents what we believe to be a novel cGMP signaling entity that is unresponsive to NO and prone to degradation. Whereas high-affinity ligands for the unoccupied heme pocket of sGC such as zinc-protoporphyrin IX and the novel NO-independent sGC activator 4-[((4-carboxybutyl){2-[(4-phenethylbenzyl)oxy]phenethyl}amino) methyl [benzoic]acid (BAY 58-2667) stabilized the enzyme, only the latter activated the NO-insensitive sGC variant. Importantly, in isolated cells, in blood vessels, and in vivo, BAY 58-2667 was more effective and potentiated under pathophysiological and oxidative stress conditions. This therapeutic principle preferentially dilates diseased versus normal blood vessels and may have far-reaching implications for the currently investigated clinical use of BAY 58-2667 as a unique diagnostic tool and highly innovative vascular therapy.
Collapse
Affiliation(s)
- Johannes-Peter Stasch
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Peter M. Schmidt
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Pavel I. Nedvetsky
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Tatiana Y. Nedvetskaya
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Arun Kumar H.S.
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Sabine Meurer
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Martin Deile
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Ashraf Taye
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Andreas Knorr
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Harald Lapp
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Helmut Müller
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Yagmur Turgay
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Christiane Rothkegel
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Adrian Tersteegen
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Barbara Kemp-Harper
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Werner Müller-Esterl
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| | - Harald H.H.W. Schmidt
- Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany.
Department of Pharmacology, Monash University, Melbourne, Victoria, Australia.
Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany.
Institute for Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany.
Helios Klinikum Erfurt, Erfurt, Germany.
Martin-Luther-University, School of Pharmacy, Halle, Germany.
Centre for Vascular Health, Monash University, Melbourne, Victoria, Australia
| |
Collapse
|